Jobs
-
The European Commission has approved Janssen Pharmaceutical’s Spravato esketamine nasal spray for the treatment of treatment-resistant major depressive disorder, the company said. The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive… Read more . . .
-
Biohaven Pharmaceutical has announced that a Phase 2/3 trial of its intranasal vazegepant (BHV-3500) demonstrated that 10 and 20 mg doses of the intranasal migraine therapy were more effective than placebo for pain relief and… Read more . . .
-
3M has announced the sale of “substantially all” of 3M Drug Delivery Systems to Altaris Capital Partners for approximately $650 million. 3M will keep a 17% interest in the new business, which is expected to… Read more . . .
-
Spray characterization specialists Oxford Lasers have opened a new contract services facility to provide drug delivery device testing at their site in Didcot, UK, the company said. Oxford Lasers Imaging Division Manager Seamus Murphy said,… Read more . . .
-
Aerosurf inhaled surfactant developer Windtree Therapeutics has announced the completion of a $26.4 million private placement of common stock and warrants. Net proceeds were approximately $23 million. Windtree is developing several inhaled drugs delivered via the company’s… Read more . . .
-
VistaGen Therapeutics has announced that its PH94B aloradine nasal spray for the treatment of social anxiety disorder (SAD) has received Fast Track designation from the FDA. The company says that it is preparing to conduct… Read more . . .
-
OINDP testing experts Copley Scientific have announced the hires of Edward Brundrett, who joins the company as a technical sales executive, and Mark Lo, a mechanical engineer who is joining the company’s design team. The company,… Read more . . .
-
Chiesi announced that the company has signed an agreement with Koura (formerly Mexichem) for supply of HFA 152a propellant as part of a €350 million plan to bring a pMDI with a 90% lower carbon… Read more . . .
-
Theravance Biopharma announced that the first patient has been dosed in a Phase 2 study of its TD-8236 inhaled dry powder pan-JAK inhibitor which the company is developing for the treatment of inflammatory lung diseases.… Read more . . .
-
Sosei Group has announced that the Ultibro Breezhaler indacaterol/glycopyrronium DPI has been added to the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of COPD. Novartis launched Ultibro Breezhaler and Seebri Breezhaler in China in… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany